Abstract 2961
Background
YF-H-2015005, a new type of CXCR4 antagonist, has demonstrated an ability to mobilize CD34+ cells in peripheral blood in pre-clinical studies. In this study, we evaluated the safety and efficacy of YF-H-2015005, as well as its pharmacokinetic (PK) and pharmacodynamic (PD) characteristics when administered with granulocyte colony-stimulating factor (G-CSF) in patients with non-Hodgkin lymphoma (NHL).
Methods
This phase I, open-label, single arm study enrolled patients who had HNL, aged 18 to 65 years, and eligible for autologous stem cell transplantation. The stem cell mobilization regimen used was G-CSF (10 mg/kg/day subcutaneously) administration in the morning for up to 8 days, and YF-H-2015005 (0.24 mg/kg subcutaneously) initialed in the evening of the fourth day of G-CSF administration, and then continued for up to 4 days. Apheresis was initiated 9 to 10 hours after each evening dose of YF-H-2015005, and after the morning dose of G-CSF. Apheresis was repeated for up to 4 days or until ≥ 2 × 106 CD34+ cells/kg had been collected.
Results
A total of 15 patients (11 men and 4 women; median age 51 years, range 32-64 years) were enrolled in the study. Our PK data showed that YF-H-2015005 was rapidly absorbed after s.c. administration with a median Tmax of 0.5 hour, and then was rapidly cleared with a terminal half-life of 5.04 ± 1.00 hours. After the first dose of YF-H-2015005, a mean 2.0-fold to 2.9-fold increase in peripheral blood CD34+ cells from baseline was observed after 2 to 24 hours, with the maximum increase being observed at 10 hours after dosing. Fourteen (93%) patients reached the minimum target CD34+ cell collection of ≥ 2 × 106 cells/kg required for transplantation. No adverse event ≥ grade 3 or treatment-related serious adverse event occurred.
Conclusions
YF-H-2015005 was safe and effective when used to mobilize CD34+ cells for transplantation in patients with NHL.
Clinical trial identification
CTR20170925.
Editorial acknowledgement
Legal entity responsible for the study
Hefei Yifan Biopharmaceuticals Inc.
Funding
Hefei Yifan Biopharmaceuticals Inc.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5751 - Phase 3 ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)−positive non–small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ)
Presenter: Sanjay Popat
Session: Poster Display session 1
Resources:
Abstract
5103 - CANOPY phase 3 program: Three studies evaluating canakinumab in patients with non-small cell lung cancer (NSCLC)
Presenter: Luis Paz-Ares
Session: Poster Display session 1
Resources:
Abstract
3666 - The Elderly Patient Individualized Chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer.
Presenter: Francesco Passiglia
Session: Poster Display session 1
Resources:
Abstract
4799 - KEYNOTE-495/KeyImPaCT: A Randomized, Biomarker-Directed, Phase 2 Trial of Pembrolizumab-Based Therapy for Non–Small Cell Lung Cancer (NSCLC)
Presenter: Martin Gutierrez
Session: Poster Display session 1
Resources:
Abstract
6035 - Safety, tolerability and activity of autologous T cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non small cell lung cancer: A Phase 1b/2a randomised pilot study
Presenter: Karen Reckamp
Session: Poster Display session 1
Resources:
Abstract
2176 - IFCT-1701 DICIPLE: a randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in patients with PDL1-positive stage IV Non-Small Cell Lung Cancer (NSCLC) after Nivolumab-Ipilimumab induction treatment
Presenter: Gerard Zalcman
Session: Poster Display session 1
Resources:
Abstract
2352 - ATALANTE-1 randomized phase 3 trial, OSE-2101 versus standard treatment as second or third line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients
Presenter: Enriqueta Felip
Session: Poster Display session 1
Resources:
Abstract
2451 - Phase Ib dose-escalation/expansion study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumours
Presenter: Nicolas Girard
Session: Poster Display session 1
Resources:
Abstract
4285 - Radiosurgery followed by Tumor Treating Fields (TTFields) for brain metastases (1-10) from NSCLC in the phase 3 METIS trial
Presenter: Minesh Mehta
Session: Poster Display session 1
Resources:
Abstract
4909 - Nivolumab plus ipilimumab (NI) versus chemotherapy plus nivolumab (CN) in squamous cell lung cancer (SqCLC): the SQUINT trial
Presenter: Lorenza Landi
Session: Poster Display session 1
Resources:
Abstract